Study of Resection Combined With Stereotactic Radiosurgery for 1 to 3 Brain Metastases
This study is to look more closely at the tumor removed during your surgery, and to follow your condition after your treatment.
The purpose of this study is to determine what side effects are common or more rare from this treatment, how well the treatment has worked for you, and to track whether you develop other brain metastases.
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Pilot Study of Resection Combined With Stereotactic Radiosurgery in Patients With Limited (1-3) Brain Metastases|
- Determine toxicity of treatment with cranial SRS and resection [ Time Frame: During treatment and long term follow-up ] [ Designated as safety issue: Yes ]
- Determine the local control of the treated lesion(s), distant brain control and overall patient survival. [ Time Frame: During treatment and long term follow-up ] [ Designated as safety issue: No ]
- Tissue from the resected brain metastases will be evaluated with immunohistochemistry and/or comparative genomic hybridization to assess for potential markers for clinical outcome as well as potential markers of radiation response. [ Time Frame: Following surgical resection ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
|Study Start Date:||March 2008|
|Estimated Study Completion Date:||June 2018|
|Estimated Primary Completion Date:||June 2018 (Final data collection date for primary outcome measure)|
Novalis Shaped Beam Surgery
Patients with limited brain metastases (mostly solitary brain metastasis) treated with Novalis Shaped Beam Surgery followed by planned craniotomy and resection of the metastases.
Radiation: Novalis Shaped Beam Surgery
Treatment using Novalis SRS
Please refer to this study by its ClinicalTrials.gov identifier: NCT00904553
|United States, New York|
|Department of Radiation Oncology, University of Rochester Medical Center|
|Rochester, New York, United States, 14642|
|Principal Investigator:||Michael Milano, MD PhD||Department of Radiation Oncology, University of Rochester Medical Center|